Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)

被引：0
|
作者：
Krueger, Klaus [1 ]
Selmi, Carlo [2 ,3 ]
Cantagrel, Alain [4 ]
Abad, Miguel A. [5 ]
Freudensprung, Ulrich [6 ]
Rezk, Mourad Farouk [6 ]
Addison, Janet [7 ]
机构：
[1] Med Ctr Rheumatol, Munich, Germany
[2] Humanitas Res Hosp, Rheumatol & Clin Immunol Unit, Rozzano, MI, Italy
[3] Univ Milan, B1OMETRA Dept, Milan, Italy
[4] CHU, Ctr Rheumatol, Toulouse, France
[5] Hosp Virgen Puerto, FEA Reumatol, Caceres, Spain
[6] Biogen Int GmbH, Zug, Switzerland
[7] Biogen Idec Inc, Maidenhead, Berks, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2537
引用
收藏
页数：2
相关论文
共 40 条
  • [21] A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence
    Dignass, A.
    Gisbert, J. P.
    Bossa, F.
    Kelly, O.
    Rahman, M.
    Lobaton, T.
    Addison, J.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 558 - 559
  • [22] Effectiveness of Upadacitinib in Patients With Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results From the CLOSE-UP Post-Marketing Observational Study
    Haaland, Derek
    Chan, Jonathan
    Lisnevskaia, Larissa
    Chow, Andrew
    Girard, Tanya
    Fournier, Pierre-Andre
    Bessette, Louis
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 83 - 83
  • [23] Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study
    Haaland, Derek
    Chan, Jonathan
    Lisnevskaia, Larissa
    Chow, Andrew
    Girard, Tanya
    Fournier, Pierre-Andre
    Bessette, Louis
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 578 - 581
  • [24] REAL-WORLD ASSESSMENT OF GP2015 (ETANERCEPT BIOSIMILAR, SDZ-ETN): AN INTERIM ANALYSIS OF DATA FROM THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE COMPACT STUDY
    Kellner, H.
    Askari, A.
    Kupka, T.
    Friccius-Quecke, H.
    Furlan, F.
    Hachaichi, S.
    Schmalzing, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1445 - 1445
  • [25] OUTCOMES OF THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE IN RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS RECEIVING GP2015 (ETANERCEPT BIOSIMILAR) IN A REAL-WORLD STUDY: FINAL RESULTS FROM COMPACT STUDY
    Schmalzing, M.
    Askari, A.
    Sheeran, T.
    Jathanakodi, S.
    Both, C.
    Kellner, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1397 - 1397
  • [26] The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
    Ulf Müller-Ladner
    Axel Dignass
    Karl Gaffney
    Deepak Jadon
    Marco Matucci-Cerinic
    Triana Lobaton
    Philippe Carron
    Javier P. Gisbert
    Ira Pande
    Maximilian Utzinger
    Janet Addison
    BioDrugs, 2023, 37 : 873 - 889
  • [27] Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
    D'Angelo, Salvatore
    Tirri, Enrico
    Giardino, Angela Maria
    Mattucci-Cerinic, Marco
    Dagna, Lorenzo
    Santo, Leonardo
    Ciccia, Francesco
    Frediani, Bruno
    Govoni, Marcello
    Pallavicini, Francesca Bobbio
    Grembiale, Rosa Daniela
    Delle Sedie, Andrea
    Mule, Rita
    Cantatore, Francesco Paolo
    Foti, Rosario
    Gremese, Elisa
    Conigliaro, Paola
    Salaffi, Fausto
    Viapiana, Ombretta
    Cauli, Alberto
    Giacomelli, Roberto
    Arcarese, Luisa
    Guggino, Giuliana
    Russo, Romualdo
    Puenpatom, Amy
    Capocotta, Domenico
    Nacci, Francesca
    Anelli, Maria Grazia
    Picerno, Valentina
    Binetti, Corrado
    Iannone, Florenzo
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (14)
  • [28] GOLIMUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIASIS ARTHRITIS (PSA) AND AXIAL SPONDYLOARTHRITIS (AXSPA): INTERIM RESULTS FROM A NON-INTERVENTIONAL STUDY IN AUSTRIA (GO ACTIVE)
    Dejacol, C.
    Mueller, T.
    Zamani, O.
    Kurtz, U.
    Egger, S.
    Resch-Passini, J.
    Totzauer, A.
    Eisterer, W.
    Yazdani-Biuki, B.
    Schwingenschloegl, T.
    Peichl, P.
    Kraus, A.
    Naerr, G. W.
    Rickert, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 598 - 599
  • [29] The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease
    Mueller-Ladner, Ulf
    Dignass, Axel
    Gaffney, Karl
    Jadon, Deepak
    Matucci-Cerinic, Marco
    Lobaton, Triana
    Carron, Philippe
    Gisbert, Javier P.
    Pande, Ira
    Utzinger, Maximilian
    Addison, Janet
    BIODRUGS, 2023, 37 (06) : 873 - 889
  • [30] Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study
    Athanassiou, Panagiotis
    Psaltis, Dimitrios
    Georgiadis, Athanasios
    Katsifis, Gkikas
    Theodoridou, Athina
    Gazi, Souzana
    Sidiropoulos, Prodromos
    Tektonidou, Maria G. G.
    Bounas, Andreas
    Kandyli, Anna
    Vounotrypidis, Periklis
    Sakellariou, Grigorios T. T.
    Vassilopoulos, Dimitrios
    Huang, Zhiping
    Petrikkou, Evangelia
    Boumpas, Dimitrios
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (10) : 1871 - 1883
1234